Kaken Pharmaceutical (4521) Q4 2025 earnings summary

Executive summary

• Net sales for FY2024 rose 30.5% year-over-year to ¥94,035 million, driven by strong overseas sales and upfront payments from licensing agreements.

• Operating profit more than doubled to ¥21,034 million, reflecting increased sales and significant licensing income.

• Profit attributable to owners of the parent increased 73.8% year-over-year to ¥13,945 million.

• Strategic investments and acquisitions, including the purchase of Aadi Subsidiary in the US, expanded the global footprint and product pipeline.

• Out-licensing agreements for NM26 and STAT6 inhibitors generated record-high upfront payments and future milestone opportunities.

Financial highlights

• Gross profit increased from ¥38,539 million to ¥58,532 million year-over-year.

• Research and development expenses rose from ¥12,543 million to ¥18,725 million.

• Net sales: ¥94,035 million (up ¥21,990 million, 30.5% YoY).

• Operating profit: ¥21,034 million (up ¥11,521 million, 121.1% YoY).

• Cash and cash equivalents at year-end increased to ¥70,085 million from ¥65,325 million.

Outlook and guidance

• FY2025 net sales forecasted at ¥88,000 million, a 6.4% decrease due to absence of large upfront payments and impact from Clenafin patent cliff.

• Operating profit expected to drop to ¥5,200 million, reflecting higher SG&A and R&D expenses.

• Profit attributable to owners of the parent forecasted at ¥3,400 million, down 75.6%.

• Basic earnings per share forecasted at ¥88.53 for the next fiscal year.

• Dividend policy revised to a minimum of ¥190 per share, with a payout ratio of 30% or higher.